Mirae Asset Global Etfs Holdings Ltd. C4 Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 35,241 shares of CCCC stock, worth $52,861. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,241
Previous 33,675
4.65%
Holding current value
$52,861
Previous $121,000
53.72%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
118Shares Held
63.1MCall Options Held
18.8KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.1MShares$10.6 Million4.2% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$10.5 Million0.92% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$10.2 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.72MShares$10.1 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$6.83 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $73.4M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...